This cluster is routine and non-informative given the small proportion of market cap sold. Monitor for any upcoming earnings or material agreements that might have triggered the sales, but no immediate trading action is warranted.
RPRX drugs
RPRX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 20 $60.57entry
- T+1 · 3mo ago +1.23%α +0.82% · $61.31
- T+5 · 3mo ago +2.24%α +1.12% · $61.92
- T+20 · 8w ago −3.56%α −3.44% · $58.41
- T+60 · 3d ago +14.44%α +15.52% · $69.31
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two senior executives at Royalty Pharma (EVP/Chairman Hite and EVP/CFO Coyne) sold a combined $6.54M in open-market sales over a 5-day window, with Hite's $6.0M sale representing the bulk. However, insider sales are generally weak predictors, and the proportionality check shows the cluster is well below the 0.1% threshold for materiality, making this a routine liquidity-driven event.
Key Financial Metrics
Key Facts
- EVP & Chairman Hite sold 100,000 shares for $6.0M on 2026-08-18
- EVP & CFO Coyne sold 9,200 shares for $541K on 2026-08-13
- Total cluster value: $6.54M, representing ~0.02% of $34.3B market cap
- Hite also gifted 16,800 shares ($0 value) on 2026-08-19, which is a non-cash event
- No 10b5-1 plan pattern identified; sales are open-market
Financial Impact
Total insider sales of $6.54M, representing 0.02% of market cap, below the 0.1% materiality threshold
Risk Factors
- Insider sales could accelerate if more executives follow
- No bearish signal from this cluster alone given the small size relative to market cap
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-RPRX-1787198895216 |
Track record
22 reports on RPRX
5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +15.20% at T+60 after the May 6, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $67.57 to $68.97 Now $68.53 +1.41% ▲ +2.07% −1.22% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 No price data
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $67.56 to $70.01 Now $68.53 +1.43% ▲ +3.63% +4.54% vs SPY
- Sep 30, 20266w ago Insider Cluster Bearish 5/10 Entry $57.63 to $56.21 Now $68.53 −18.91% ▲ +2.46% +3.77% vs SPY
- Sep 4, 202610w ago Press Release Bearish 5/10 Entry $60.59 to $58.47 Now $68.53 −13.10% ▲ +3.50% +2.38% vs SPY
- Aug 19, 202612w ago Insider Cluster Neutral 3/10 Viewing Entry $60.57 to $61.92 Now $68.53 +13.14% ▲ +2.24% +1.12% vs SPY
- Aug 12, 202613w ago 144 Neutral 3/10 Entry $58.56 to $60.58 Now $68.53 +17.02% ▲ +3.45% +5.41% vs SPY
- Aug 5, 202614w ago 8-K Bullish 6/10 Entry $57.75 to $59.22 Now $68.53 +18.66% ▲ +2.55% +2.19% vs SPY
- Jul 2, 202619w ago Insider Cluster Neutral 2/10 Entry $57.77 to $57.96 Now $68.53 +18.62% ▲ +0.33% −0.60% vs SPY
- Jul 2, 202619w ago Insider Cluster Neutral 2/10 Entry $57.77 to $57.96 Now $68.53 +18.62% ▲ +0.33% −0.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers